ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS

ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS

Show other versions (1)

Long-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation. We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in...

Full description

Saved in:
Bibliographic Details
Main Authors: saveria capria, silvia maria trisolini, clara minotti, caterina stefanizzi, luisa cardarelli, Martina Canichella, claudio cartoni, daniela diverio, maria stefania de propris, marco mancini, alessandra micozzi, robin foà, giovanna meloni
Format: Article
Language:English
Published: PAGEPress Publications 2012-11-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
Leukemia
Gentuzumab Ozogamicin
Allogeneic stem cell transplantation
Online Access:http://www.mjhid.org/index.php/mjhid/article/view/378
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Long-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation. We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in relapsed/refractory AML. The main endpoints were: the rate of complete remissions (CR) and the proportion of patients capable of undergoing a stem cell transplant. Fourty-two patients were enrolled. The overall CR rate was 76% and no induction deaths were reported. In 56% of patients, a transplant procedure could be performed. The treatment schedule proved feasible and well tolerated, providing a high CR rate and a useful bridge to transplant.
ISSN:2035-3006

Similar Items